Results 61 to 70 of about 48,138 (255)

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

British Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem, Mohannad N. AbuHaweeleh, Humam Emad Rajha, Mhd Osama Rahhal, Ahmad Hamdan, Lina Naseralallah   +5 more
wiley   +1 more source

Criteria Suggestive of Psychological Components of Itch and Soma­toform Itch: Study of a Large Sample of Patients with Chronic Pruritus

Acta Dermato-Venereologica, 2020
While psychological factors are relevant in many patients with chronic pruritus, not all patients can be offered psychologic, psychosomatic or psychiatric consultation.
Gudrun Schneider, Anna Grebe, Philipp Bruland, Gereon Heuft, Sonja Ständer   +4 more
doaj   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study

Acta Dermato-Venereologica
The occurrence of pruritus in psoriasis was previously underestimated but is a significant burden. Secukinumab (SEC), a monoclonal anti-interleukin-17A antibody, efficiently controls signs of psoriasis, but the effect on pruritus and cutaneous ...
Lina Renkhold, Manuel P. Pereira, Karin Loser, Dieter Metze, Daniel Baeumer, Nima Melzer, Maximilian Reinhardt, Athanasios Tsianakas, Thomas Luger, Christian Mess, Ruth Becker, Clara Hambüchen, Konstantin Agelopoulos, Sonja Ständer   +13 more
doaj   +1 more source

A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST)

American Journal of Hematology, EarlyView.
Kenneth I. Ataga, Pablo Bartolucci, Santosh L. Saraf, Vimal K. Derebail, Adlette Inati, Jeffrey D. Lebensburger, Laurie DeBonnett, Rodolfo D. Cancado, Claire C. Sharpe   +8 more
wiley   +1 more source

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

Clinical Pharmacology &Therapeutics, EarlyView.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi, Mwila Mulubwa, Mmakwena M. Mmonwa, Mathew Njoroge, Liezl Krugmann, Kelly Chibale   +5 more
wiley   +1 more source

Generalized chronic pruritus with fibromyalgia [PDF]

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2021
Max, Görg, Claudia, Zeidler, Manuel P, Pereira, Sonja, Ständer   +3 more
openaire   +2 more sources

Adverse Reactions Identified after Approval of Novel Medicines: Analysis of 339 New Molecular Entities and Therapeutic Biologics

Clinical Pharmacology &Therapeutics, EarlyView.
Postmarketing safety surveillance data identify safety issues not identified in preapproval clinical trials. We describe the frequency of new safety issues overall and by labeling section and the relationship of the most commonly added safety issues with the cumulative number of prescriptions dispensed via retail pharmacies.
Ellen Pinnow, Brendan Day, Esther H. Zhou, Corinne Woods, Nana Dwumfour, Jenni Y. Lee, Ilynn Bulatao, Sanae Cherkaoui, Manish Kalaria, Sonja Brajovic, Nabila Sadiq, Farideh Sistani, Maggie Lee, Grace Chai, Gerald Dal Pan   +14 more
wiley   +1 more source

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison

Dermatology and Therapy
Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 
Sonja Ständer, Andreas Pinter, Firas G. Hougeir, Patricia Guyot, Yingxin Xu, Amy H. Praestgaard, Nick Freemantle, Ana B. Rossi, Gaëlle Bégo-Le-Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian   +11 more
doaj   +1 more source

Epidemiology of Chronic Kidney Diseases (CKD) in Malaysia and Pakistan, Pathophysiology of CKD-Associated Pruritus and Other CKD-Associated Dermatological Disorders

Progress in Microbes and Molecular Biology, 2020
Almost 50–90% of chronic kidney disease patients undergoing haemodialysis have been reported to have Chronic kidney disease-associated pruritus (CKD-aP).
Inayat Ur Rehman, Tahir Mehmood Khan
doaj   +1 more source